Objective Indicia Not Enough to Overcome Weight of Evidence of Obviousness
In Merck Sharp & Dohme Corp. v. Hospira, Inc., [2017-1115] (October 26, 2017), the Federal Circuit affirmed the district court’s determination at a bench trial, that claims 21-34 of U.S. Patent 6,486,150, on a method for preparing the antibiotic ertapenem were invalid for … Continue reading Objective Indicia Not Enough to Overcome Weight of Evidence of Obviousness
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed